• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconEli Lilly

Eli Lilly

Page 3 of 7
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
Health
Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says
By Lindsey LeakeOctober 10, 2024
Tesla CEO Elon Musk attends the 10th Annual Breakthrough Prize Ceremony at Academy Museum of Motion Pictures.
Health
Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic
By Christiaan HetznerSeptember 25, 2024
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
Health
Roche stock is falling after report its Wegovy challenger is causing patients to vomit
By Naomi Kresge and BloombergSeptember 12, 2024
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
Newsletters
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
By Sheryl EstradaSeptember 10, 2024
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
Newsletters
In this year’s Global 500 list: Energy woes, retail gains, and boom times for AI and weight-loss drugs
By Lydia BelangerAugust 5, 2024
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
Magazine
How Eli Lilly went from pharmaceutical slowpoke to $791 billion juggernaut
By Erika FryAugust 2, 2024
Thomas Schinecker, chief executive officer of Roche
Finance
Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss
By Prarthana PrakashJuly 29, 2024
A bathroom scale is surrounded by colorful pills.
Health
Pharma giant Pfizer is trying to cash in on the weight loss drug craze with a new pill that could be a welcome needle-free alternative to pesky GLP-1 shots
By Damian Garde and BloombergJuly 11, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features
Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree
By Jessica Mathews and Alena BotrosJuly 9, 2024
Alzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
Commentary
Alzheimer’s made my mom unable to recognize her grandkids. Breakthroughs too late for her can change the disease’s trajectory—if diagnosis and treatment start early
By Anne E. WhiteJuly 2, 2024
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
Health
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
Alzheimer’s drug from Eli Lilly that can slow brain-robbing disease backed by FDA advisers
Health
Alzheimer’s drug from Eli Lilly that can slow brain-robbing disease backed by FDA advisers
By Matthew Perrone and The Associated PressJune 11, 2024
Nestle CEO Mark Schneider
Retail
Nestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
By Sasha RogelbergMay 21, 2024
Lars Fruergaard Jorgensen, chief executive officer Novo Nordisk
Retail
Denmark’s Novo Nordisk forecasts 27% sales surge but faces price pressure amid Eli Lilly competition
By Naomi Kresge and BloombergMay 2, 2024
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
Health
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer’s drug
By Tom Murphy, Matthew Perrone and The Associated PressMarch 8, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...7
Most Popular
Economy
U.S. set to pay most for 30-year debt in quarter of a centuryplaceholder alt text
By Greg Ritchie and BloombergAugust 13, 2026
North America
Google cofounder Sergey Brin has now spent $100 million to fight California’s proposed billionaire tax—he could owe $13 billion if he losesplaceholder alt text
By Sasha RogelbergAugust 11, 2026
Personal Finance
Current price of oil as of August 13, 2026placeholder alt text
By Joseph HostetlerAugust 13, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.